Latest Updates on Monoclonal Antibodies
WebMD’s Chief Medical Officer, John Whyte, MD, speaks with George Yancopoulos, MD, PhD, President & Chief Scientific Officer, Regeneron Pharmaceuticals Inc., about the latest updates on monoclonal antibodies.
Related Articles
Osteoporosis: Assessing Risk of Fragility Fracture
This NICE guideline summary discusses risk assessment for fragility fracture in osteoporosis
Is Nighttime the Best Time for Exercise?
The timing of moderate to vigorous physical activity was associated with a lower risk for mortality and CVD in adults with obesity, including those with…
Menstrual Bleeding, Heavy
Includes recommendations on management and investigations on the causes of heavy menstrual bleeding, also covering history taking, diagnosis, and provision of information
Let’s Get Social About Cosmetic Procedures in Skin of Color
Other event by Medscape on Wednesday, April 24 2024
Are Direct-to-Consumer Microbiome Tests Clinically Useful?
Some companies claim they can identify and treat gastrointestinal problems with proprietary technology and products — experts disagree.
Less Gut Microbial Diversity in Patients With Prediabetes
Compared with healthy individuals, Asian patients with prediabetes had relatively less abundance of gut bacteria associated with normal physiological functions and metabolism.
Endometriosis: Diagnosis and Management
This summary provides information on the signs and symptoms of endometriosis, diagnosis and referral, and pharmacological pain management
Getting Patients With Opioid Use Disorder Started on Buprenorphine in Primary Care
Former obstacles are no longer an issue to prescribing the drug.
Semaglutide Improves Knee Osteoarthritis Pain, Physical Function in Phase 3 Trial
Results of the STEP 9 study in people with knee OA and obesity show that semaglutide not only induced significant weight loss but also improved…
New Screening Protocol May Improve Prostate Cancer Detection
However, it’s not yet clear whether a new three-phase screening intervention, which incorporates PSA test, a four-kallikrein panel, and MRI, will reduce prostate cancer mortality.